The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
|Articles|February 8, 2022
Rheumatoid Arthritis Quiz: Risk Factors for Fatigue in RA
Author(s)Ingrid Torjesen
Some patients with rheumatoid arthritis will complain of fatigue, but do you know which patients are most at risk? Take this quiz on the risk factors for fatigue to find out.
Advertisement
What proportion of patients with early rheumatoid arthritis are likely to experience fatigue?
Advertisement
Related to this article
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement